Ionis Pharmaceuticals Inc header image

Ionis Pharmaceuticals Inc

IONS

Equity

ISIN null / Valor 30877188

NASDAQ (2026-11-06)
USD 39.42+1.60%

Ionis Pharmaceuticals Inc
UMushroom community rating:

star star star star star
3.63 2 votes No rating yet
NegativeNeutralPositive

About company

Ionis Pharmaceuticals Inc., headquartered in Carlsbad, California, is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics. Established in 1989, Ionis has pioneered the field of antisense technology, which involves designing drugs to bind to specific RNA molecules, thereby modulating the production of proteins associated with various diseases. The company has a robust pipeline of drugs targeting a range of conditions, including cardiovascular, neurological, and rare diseases. A notable product in their portfolio is TRYNGOLZA™ (olezarsen), which is aimed at treating conditions related to elevated triglycerides. Ionis operates independently in the U.S. market while leveraging strategic partnerships to expand its global reach. Additionally, its wholly-owned subsidiary, Akcea Therapeutics, focuses on developing and commercializing treatments for patients with serious and rare diseases. Ionis is publicly traded on the Nasdaq under the ticker symbol IONS.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-46.8%1Y
-14.8%3Y
17.0%5Y

Performance

44.5%1Y
44.2%3Y
44.0%5Y

Volatility

Market cap

6551 M

Market cap (USD)

Daily traded volume (Shares)

2,911,841

Daily traded volume (Shares)

1 day high/low

35.5 / 34.85

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.63

2 votes
Performance:
starstarstarstarstar
3.63
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
4.38
Nature:
starstarstarstarstar
2.63
Joseph Dobler
UK, 20 Oct 2026
star star star star star
Good returns, volatile
Enzo Kekligian
UK, 03 Nov 2025
star star star star star
great

EQUITIES OF THE SAME SECTOR

Biogen Inc
Biogen Inc Biogen Inc Valor: 1720684
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.81%USD 248.35
Zydus Lifesciences Limited
Zydus Lifesciences Limited Zydus Lifesciences Limited Valor: 29835501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.12%INR 1,195.00
IPCA Laboratories Limited
IPCA Laboratories Limited IPCA Laboratories Limited Valor: 115718957
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%INR 1,942.95
AnaptysBio, Inc.
AnaptysBio, Inc. AnaptysBio, Inc. Valor: 29675116
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.91%USD 46.45
LeMaitre Vascular inc
LeMaitre Vascular inc LeMaitre Vascular inc Valor: 2755054
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.11%USD 80.89
GSK PLC
GSK PLC GSK PLC Valor: 120042705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.16%USD 50.33
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited Valor: 3195888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.32%INR 2,592.85
GSK PLC
GSK PLC GSK PLC Valor: 119642297
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 18.90
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.77%GBP 16.50
Piramal Pharma Limited
Piramal Pharma Limited Piramal Pharma Limited Valor: 114197705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.17%INR 239.20